About This Casebook

What the casebook covers

Assent Peptides keeps a casebook on two incretin-class peptides studied for metabolic regulation and weight management: retatrutide and tirzepatide. The aim is to make a fast-moving, technically dense, and frequently overclaimed literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which populations, at what doses, and how far that evidence reaches.

The organizing frame is the incretin trajectory: tirzepatide is the approved dual agonist against which retatrutide's triple-agonist Phase 3 data will ultimately be measured. Read side by side — mechanism, evidence depth, regulatory status, safety signals — they give context that neither offers alone. Each has its own page; a comparison page sets them together; and a single references list gathers every source.

How the casebook is kept

Three rules govern the casebook.

Everything rests on the peer-reviewed literature. Every research claim carries a numbered citation — chiefly PubMed-indexed articles, Phase 1/2/3 clinical-trial publications, and systematic reviews — collected on the references page. Where a finding comes from a Phase 2 trial rather than an approved indication, that line is drawn explicitly.

Evidence is reported at its true strength. Trial results stay in the populations and durations where they were studied — never stretched into general recommendations or bent into personal-use guidance. Regulatory status, WADA status, and the limits of the data are stated plainly. For an investigational compound, "investigational" appears wherever the context calls for it, not once in a disclaimer and never again.

No comparison outruns the controlled data. Retatrutide and tirzepatide trials differ in populations, durations, and enrolled doses; apparent numeric gaps are not treated as head-to-head evidence where no such trial exists.

Where the casebook stops

Assent Peptides is not a store, not a clinic, and not a source of medical advice. Nothing is sold, supplied, sourced, or brokered here, and no affiliate or referral tie connects it to any vendor. No clinicians staff the casebook, no conditions are diagnosed, and nothing is prescribed; no dose, schedule, or route is named for anyone.

The peptides here are prescription medicines or investigational compounds. Neither is approved for over-the-counter or unmonitored use. A reader with a condition addressed in the underlying research should consult a licensed clinician in their jurisdiction. What the site offers is a calm, accurate account of the published literature — no more, and no less.